Table 4 |
|||
|
Study drug safety and tolerability |
|||
|
Placebo N = 25 |
Heparin N = 25 |
P value |
|
|
|
|||
|
Percentage of scheduled doses withheld |
3.8 ± 9.2 |
5.8 ± 9.5 |
0.5 |
|
Reasons for withholding |
|||
|
Blood-stained sputum |
1 (4) |
6 (24) |
0.1 |
|
Prolonged APTT |
1 (4) |
3 (12) |
0.6 |
|
Suspected HIT |
0 |
1 (4) |
1 |
|
Confirmed HIT |
1 (4) |
0 |
1 |
|
Invasive procedure |
3 (12) |
0 |
0.2 |
|
Other |
4 (16) |
2 (8) |
0.7 |
|
Percentage of days during study period with |
|||
|
Blood-stained sputum |
31 ± 28 |
41 ± 39 |
0.3 |
|
Frank blood in sputum |
2.5 ± 9 |
7.0 ± 21 |
0.3 |
|
Purulent sputuma |
62 ± 25 |
61 ± 35 |
1 |
|
Red cell transfusion |
|||
|
Volume transfused per day (mls) |
0 (0-57) |
0 (0-85) |
0.9 |
|
Patients transfused |
10 (40) |
7 (28) |
0.4 |
|
Abnormal APTTb (> 40 seconds) |
5/17 (29) |
11/19 (58) |
0.08 |
|
|
|||
|
aDenotes sputum reported as yellow, green, dirty, or purulent. bPatients on therapeutic heparin were excluded from this analysis. Values other than P values are presented as mean ± standard deviation, as median (interquartile range), or as number (percentage). APPT, activated partial thromboplastin time; HIT, heparin-induced thrombocytopenia. |
|||
|
Dixon et al. Critical Care 2010 14:R180 doi:10.1186/cc9286 |
|||
